The Swiss Zur Rose Group AG has acquired TeleClinic GmbH, based in Munich, for a purchase price in the mid double-digit million euro range. The fast-growing start-up, which was founded in 2015 by Katharina J\u00fcnger, has quickly established itself as a leading telemedicine provider in Germany and is considered a pioneer in the field of telemedical services, including digital prescriptions and medical certificates. As the acceptance and penetration of digital healthcare services increases significantly as a result of the COVID-19 pandemic, TeleClinic is expected to further expand its market position. <\/p>\n\n
The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. The company has an international presence with strong brands, including Germany’s best-known pharmacy brand DocMorris. Zur Rose employs over 1,800 people in Europe and generated sales of over 1.5 billion Swiss francs in 2019 with around nine million active customers in core European markets. <\/p>\n\n
Renzenbrink & Partner already advised TeleClinic on the last financing round in 2018 and has now also been mandated to advise the seller on the exit transaction. The advice covered all (tax) legal aspects of the sale. The Renzenbrink & Partner team consisted of partners Dr. Dennis Schlottmann<\/a> (Corporate\/M&A) and Marc Kotyrba<\/a> (Tax) as well as associate Dr. Alexander Haunschild<\/a> (Corporate\/M&A). <\/p>\n","protected":false},"featured_media":1346,"template":"","class_list":["post-1356","deals","type-deals","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n